Credit: REUTERS/BRENDAN MCDERMIDAug 29 (Reuters) - AbbVie Inc ABBV.N on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo.
An independent data monitoring committee recommended terminating the trial after an interim analysis of data from the trial testing its treatment, Rova-T, as first-line therapy, the company said.
AbbVie last year halted enrollment in a trial testing Rova-T as a second-line therapy in lung cancer.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
